Intranasal AST-726 treatment for prophylaxis of migraine: a placebo-controlled clinical study
Latest Information Update: 05 Aug 2019
At a glance
- Drugs Hydroxocobalamin (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Ariston Pharmaceuticals
- 14 Feb 2008 The expected completion date for this trial is now 1 Jun 2008.
- 07 Feb 2008 Status changed from recruiting to in progress according to NCT.
- 29 May 2007 Status change from initiated to recruiting.